Studieoverzicht
Study name: First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations. (M23STX)
Histology | NSCLC | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | Antoni van Leeuwenhoek | Enrollment | Recruiting |
Therapy line | Later line (≥2L) | ||
Design |
Dosisescalatie en daarna dosisexpansie open-label fase I/II onderzoek naar antitumoractiviteit van STX-721 bij niet-kleincellig longcarcinoom en drager van EGFR/HER2 activerende exon 20 insertie-mutaties. |
||
Intervention | Monotherapie STX-721 is een orale selectieve EGFR- en HER2-ex20ins-inhibitor |
||
Key outcome parameters |
|
||
Key inclusion criteria |
|
||
Key exclusion criteria |
|
||
Contact information | Log in voor de contactinformatie |